“Tardive dyskinesia can significantly impact many aspects of patients’ lives, including daily activities, work or school attendance and social interactions,” said Eiry W. Roberts, M.D., Chief Medical ...
Biosciences announced the presentation of a new post-hoc analysis from the Phase 3, open-label KINECT 4 study, demonstrating that patients treated continuously for 48 weeks with the 40 mg dose of once ...
The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from ...
SAN DIEGO, May 15, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced findings from a post hoc analysis of two long-term studies (KINECT™ 3 and KINECT™ 4) of ...
Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia Findings Presented at the 2025 American ...
SAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT ® 4 study demonstrating remission of tardive ...
SAN DIEGO, Feb. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback